|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM076580156 |
| 003 |
DE-627 |
| 005 |
20231222031715.0 |
| 007 |
tu |
| 008 |
231222s1993 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0256.xml
|
| 035 |
|
|
|a (DE-627)NLM076580156
|
| 035 |
|
|
|a (NLM)7682030
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Kitamura, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer
|
| 264 |
|
1 |
|c 1993
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.05.1993
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We analyzed the excretion of the three urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and glycyl-prolyl dipeptidyl aminopeptidase (GP-DAP) and the three urinary proteins, beta-microglobulin (beta 2-M), alpha-microglobulin (alpha 1-M), and albumin during the intravenous administration of anti cancer drugs in 4 prostatic cancer patients and 16 urothelial cancer patients. The patients with prostatic cancer were treated with VIP (vincristine, ifosfamide, peplomycin) chemotherapy and the patients with urothelial cancer were treated with MP (methotrexate, cisplatinum) or MEP (methotrexate, Etoposide, cisplatinum) combination chemotherapy. beta 2-M was the best parameter for drug-induced renal damage because of its sharp and large reactivities. Any urinary enzyme or protein especially albumin which had showed a markedly high value before the chemotherapy was not suitable as a urinary drug-induced renal damage parameter. There was a close resemblance in reactivity pattern between GP-DAP and AAP probably because of the same localization of these enzymes in the renal tubular bruch borders. In the patients with renal damage by chemotherapy, all parameters were changed showing two peaks or persisted with high values
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Bleomycin
|2 NLM
|
| 650 |
|
7 |
|a 11056-06-7
|2 NLM
|
| 650 |
|
7 |
|a Vincristine
|2 NLM
|
| 650 |
|
7 |
|a 5J49Q6B70F
|2 NLM
|
| 650 |
|
7 |
|a Etoposide
|2 NLM
|
| 650 |
|
7 |
|a 6PLQ3CP4P3
|2 NLM
|
| 650 |
|
7 |
|a Acetylglucosaminidase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.2.1.52
|2 NLM
|
| 650 |
|
7 |
|a Aminopeptidases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.11.-
|2 NLM
|
| 650 |
|
7 |
|a CD13 Antigens
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.11.2
|2 NLM
|
| 650 |
|
7 |
|a Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.14.-
|2 NLM
|
| 650 |
|
7 |
|a Dipeptidyl Peptidase 4
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.14.5
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 650 |
|
7 |
|a Ifosfamide
|2 NLM
|
| 650 |
|
7 |
|a UM20QQM95Y
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Watanabe, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Komatsubara, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sakata, Y
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 39(1993), 2 vom: 28. Feb., Seite 135-40
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:39
|g year:1993
|g number:2
|g day:28
|g month:02
|g pages:135-40
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 39
|j 1993
|e 2
|b 28
|c 02
|h 135-40
|